Gilead delivered healthy earnings as a result of the huge sales of its hepatitis C drug Solvaldi. David Nelson, Chief Strategist at Belpointe Asset Management believes the stock could continue to move higher. Even though insurers are pushing back about the price of the treatment, Gilead wants to recoup the cost of research to develop the drug. Plus, taking the drug for a one time treatment prevents more expensive consequences of not taking the drug, like liver disease.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside